| COMPOSITION | |
|---|---|
| ITRACONAZOLE DUSTING POWDER | 1% |
ITRACONAZOLE DUSTING POWDER
FUNGIVICE DUSTING POWDER
| SPECIFICATION | |
|---|---|
| FORM | POWDER |
| PACKING | 75GM |
| PACKING TYPE | DUSTING POWDER |
| MRP | 180 |
DESCRIPTION
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis. [PubChem]
SIDE EFFECTS
No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg.
INDICATION
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.